A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 47,300 shares of RCKT stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,300
Previous 29,400 60.88%
Holding current value
$1.02 Million
Previous $881,000 44.61%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$26.16 - $30.74 $320,512 - $376,626
12,252 Added 0.5%
2,469,813 $66.5 Million
Q4 2023

Feb 14, 2024

SELL
$16.78 - $31.94 $3.71 Million - $7.06 Million
-220,940 Reduced 8.25%
2,457,561 $73.7 Million
Q3 2023

Nov 14, 2023

BUY
$15.07 - $24.05 $1.36 Million - $2.17 Million
90,393 Added 3.49%
2,678,501 $54.9 Million
Q2 2023

Aug 14, 2023

SELL
$16.59 - $23.6 $1.18 Million - $1.67 Million
-70,841 Reduced 2.66%
2,588,108 $51.4 Million
Q1 2023

May 15, 2023

BUY
$15.79 - $22.6 $888,487 - $1.27 Million
56,269 Added 2.16%
2,658,949 $45.5 Million
Q4 2022

Feb 14, 2023

BUY
$15.5 - $22.76 $13 Million - $19.1 Million
838,759 Added 47.55%
2,602,680 $50.9 Million
Q3 2022

Nov 14, 2022

BUY
$12.37 - $18.41 $3.17 Million - $4.71 Million
256,082 Added 16.98%
1,763,921 $28.2 Million
Q2 2022

Aug 15, 2022

SELL
$7.96 - $16.64 $2.22 Million - $4.63 Million
-278,416 Reduced 15.59%
1,507,839 $20.7 Million
Q1 2022

May 16, 2022

BUY
$13.16 - $23.68 $1.23 Million - $2.21 Million
93,289 Added 5.51%
1,786,255 $28.3 Million
Q4 2021

Feb 14, 2022

BUY
$21.52 - $36.02 $8.48 Million - $14.2 Million
393,990 Added 30.33%
1,692,966 $37 Million
Q3 2021

Nov 15, 2021

BUY
$27.42 - $48.97 $13.7 Million - $24.5 Million
501,297 Added 62.84%
1,298,976 $38.8 Million
Q2 2021

Aug 16, 2021

BUY
$39.41 - $47.25 $4.37 Million - $5.24 Million
110,881 Added 16.14%
797,679 $35.3 Million
Q1 2021

May 17, 2021

SELL
$43.34 - $65.91 $27.4 Million - $41.7 Million
-632,105 Reduced 47.93%
686,798 $30.5 Million
Q4 2020

Feb 16, 2021

BUY
$23.3 - $59.57 $4.83 Million - $12.3 Million
207,094 Added 18.63%
1,318,903 $72.3 Million
Q3 2020

Nov 16, 2020

BUY
$20.5 - $28.59 $781,152 - $1.09 Million
38,105 Added 3.55%
1,111,809 $25.4 Million
Q2 2020

Aug 14, 2020

BUY
$13.32 - $22.61 $103,030 - $174,888
7,735 Added 0.73%
1,073,704 $22.5 Million
Q1 2020

May 15, 2020

SELL
$9.71 - $25.11 $1.69 Million - $4.36 Million
-173,689 Reduced 14.01%
1,065,969 $14.9 Million
Q4 2019

Feb 14, 2020

BUY
$11.07 - $24.23 $514,278 - $1.13 Million
46,457 Added 3.89%
1,239,658 $28.2 Million
Q3 2019

Nov 14, 2019

BUY
$10.85 - $14.78 $857,508 - $1.17 Million
79,033 Added 7.09%
1,193,201 $13.9 Million
Q2 2019

Aug 14, 2019

BUY
$15.0 - $19.81 $265,410 - $350,518
17,694 Added 1.61%
1,114,168 $16.7 Million
Q1 2019

May 15, 2019

BUY
$13.45 - $19.01 $218,118 - $308,285
16,217 Added 1.5%
1,096,474 $0
Q4 2018

Feb 14, 2019

BUY
$11.21 - $23.53 $3.61 Million - $7.58 Million
322,211 Added 42.51%
1,080,257 $16 Million
Q3 2018

Nov 13, 2018

SELL
$18.5 - $25.49 $1.31 Million - $1.81 Million
-71,020 Reduced 8.57%
758,046 $0
Q2 2018

Aug 10, 2018

BUY
$14.58 - $23.0 $5.97 Million - $9.42 Million
409,564 Added 97.63%
829,066 $0
Q1 2018

May 11, 2018

BUY
$11.68 - $19.19 $4.9 Million - $8.05 Million
419,502 New
419,502 $7.87 Million

Others Institutions Holding RCKT

About ROCKET PHARMACEUTICALS, INC.


  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $1.63B
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.